应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
06160 百济神州
已收盘 07-29 16:08:29
185.900
+4.500
+2.48%
最高
188.800
最低
178.000
成交量
909.08万
今开
180.000
昨收
181.400
日振幅
5.95%
总市值
2,863亿
流通市值
2,649亿
总股本
15.40亿
成交额
16.81亿
换手率
0.64%
流通股本
14.25亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
港股收评:午后回升!恒指小幅下跌0.15%,创新药涨幅抢眼,三胎概念股高开低走
格隆汇 · 08:21
港股收评:午后回升!恒指小幅下跌0.15%,创新药涨幅抢眼,三胎概念股高开低走
百济神州07月29日主力净流入3099.2万元 散户资金抛售
市场透视 · 08:16
百济神州07月29日主力净流入3099.2万元 散户资金抛售
基金二季报陆续披露,中欧葛兰等基金经理加码创新药板块
全景网 · 07:19
基金二季报陆续披露,中欧葛兰等基金经理加码创新药板块
百济神州:百泽安获欧洲药品管理局人用药品委员会积极意见
智通财经 · 02:45
百济神州:百泽安获欧洲药品管理局人用药品委员会积极意见
智通港股早知道 | 育儿补贴制度实施方案发布 药明康德(02359)来自美国客户收入同比增长38.4%
智通财经 · 07-28 23:28
智通港股早知道 | 育儿补贴制度实施方案发布 药明康德(02359)来自美国客户收入同比增长38.4%
国内稀缺、研发实力强!7家创新药企手握重磅新药
巨丰投顾 · 07-28 21:59
国内稀缺、研发实力强!7家创新药企手握重磅新药
百济神州百泽安®获欧洲药品管理局人用药品委员会积极意见,支持其用于非小细胞肺癌患者新辅助/辅助治疗
百济神州 · 07-28 10:04
百济神州百泽安®获欧洲药品管理局人用药品委员会积极意见,支持其用于非小细胞肺癌患者新辅助/辅助治疗
港股异动 | 百奥赛图-B(02315)涨超3% 近日宣布与百济神州达成抗体分子全球许可协议
智通财经 · 07-28 03:20
港股异动 | 百奥赛图-B(02315)涨超3% 近日宣布与百济神州达成抗体分子全球许可协议
百济神州-U股价微跌0.19% 二季度获201家基金重仓
金融界 · 07-24
百济神州-U股价微跌0.19% 二季度获201家基金重仓
新事丨罗氏终止TIGIT全部三期临床
健识局 · 07-24
新事丨罗氏终止TIGIT全部三期临床
百济潜在 BIC 蛋白降解剂获批新临床
Insight数据库 · 07-23
百济潜在 BIC 蛋白降解剂获批新临床
券商资管系公募,排名来了!
中国基金报 · 07-22
券商资管系公募,排名来了!
百济神州盘中异动 早盘快速上涨3.02%
市场透视 · 07-22
百济神州盘中异动 早盘快速上涨3.02%
博时基金唐屹兵旗下博时上证科创板100ETF中报最新持仓,重仓百济神州
证券之星 · 07-20
博时基金唐屹兵旗下博时上证科创板100ETF中报最新持仓,重仓百济神州
百济神州(ONC)盘前涨近4% 机构料公司第二季收入按年升33%至12亿美元
金吾财讯 · 07-18
百济神州(ONC)盘前涨近4% 机构料公司第二季收入按年升33%至12亿美元
鹏华基金苏俊杰旗下鹏华上证科创板100ETF中报最新持仓,重仓百济神州
证券之星 · 07-17
鹏华基金苏俊杰旗下鹏华上证科创板100ETF中报最新持仓,重仓百济神州
全网打捞:下一个大BD
阿基米德Biotech · 07-17
全网打捞:下一个大BD
百济神州07月17日获主力大幅加仓2.2亿元
市场透视 · 07-17
百济神州07月17日获主力大幅加仓2.2亿元
创新药再获热炒 恒生医疗ETF涨4.37% 乐普生物(02157)涨两成 机构称价值重估驱动行情
金吾财讯 · 07-17
创新药再获热炒 恒生医疗ETF涨4.37% 乐普生物(02157)涨两成 机构称价值重估驱动行情
百济神州-U股价微跌0.56% 生物制药板块活跃度受关注
金融界 · 07-16
百济神州-U股价微跌0.56% 生物制药板块活跃度受关注
加载更多
公司概况
公司名称:
百济神州
所属市场:
SEHK
上市日期:
--
主营业务:
BeiGene Ltd是一家全球生物技术公司,致力于为全球癌症患者发现和开发肿瘤治疗方法。该公司已发现并开发三种批准药物,包括BRUKINSA,一种布鲁顿酪氨酸激酶的小分子抑制剂,用于治疗各种血癌;TEVIMBRA(tislelizumab),一种抗PD-1抗体免疫疗法,用于治疗各种实体瘤和血癌;以及是聚ADP核糖聚合酶1(PARP1)和PARP2的选择性小分子抑制剂pamiparib。该公司已获得在美国、中华人民共和国(中国)、欧盟、英国、加拿大、澳大利亚和其他国际市场销售BRUKINSA,在欧盟和中国销售替雷利珠单抗,以及在中国销售帕米帕尼的批准。它还专注于在Amgen Inc独家授权下在中国商业化癌症药物,如XGEVA、BLINCYTO、KYPROLIS等。
发行价格:
--
{"stockData":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":185.9,"timestamp":1753776509006,"preClose":181.4,"halted":0,"volume":9090808,"delay":0,"floatShares":1425000000,"shares":1540000000,"eps":-3.6979197739226,"marketStatus":"已收盘","change":4.5,"latestTime":"07-29 16:08:29","open":180,"high":188.8,"low":178,"amount":1681282304,"amplitude":0.059537,"askPrice":185.9,"askSize":48700,"bidPrice":185.8,"bidSize":38600,"shortable":3,"etf":0,"ttmEps":-2.2361645341078575,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753839000000},"marketStatusCode":5,"adr":0,"listingDate":1533657600000,"exchange":"SEHK","adjPreClose":181.4,"openAndCloseTimeList":[[1753752600000,1753761600000],[1753765200000,1753776000000]],"volumeRatio":1.75079,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":245.78,"timestamp":1753772400000,"preClose":241.42,"halted":0,"volume":2740500,"delay":0,"premium":"-30.82"}},"requestUrl":"/m/hq/s/06160","defaultTab":"news","newsList":[{"id":"2555035386","title":"港股收评:午后回升!恒指小幅下跌0.15%,创新药涨幅抢眼,三胎概念股高开低走","url":"https://stock-news.laohu8.com/highlight/detail?id=2555035386","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555035386?lang=zh_cn&edition=full","pubTime":"2025-07-29 16:21","pubTimestamp":1753777290,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["METmain","09618","601288","06160","161726","HSCEI","MPNGY","BIDU","01024","02359","159992","BABA","03690","01398","TTTN","HHImain","03086","07226","MHImain","YANG","601939","JD","TCHmain","KSTmain","603259","01288","01810","HSI","HSImain","TCEHY","08496","MCHmain","HTCD.SI","02186","01530","399441","MIUmain","01801","688428","HSTECH","09969","601398","00700","01093","ONC","00939","688235","ALBmain","06978"],"gpt_icon":0},{"id":"2555031360","title":"百济神州07月29日主力净流入3099.2万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2555031360","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555031360?lang=zh_cn&edition=full","pubTime":"2025-07-29 16:16","pubTimestamp":1753776963,"startTime":"0","endTime":"0","summary":"07月29日, 百济神州股价涨2.48%,报收185.90元,成交金额16.8亿元,换手率0.64%,振幅5.95%,量比1.75。百济神州今日主力资金净流入3099.2万元,上一交易日主力净流出2061.7万元。该股近5个交易日上涨4.99%,主力资金累计净流入6348.2万元,其中2个交易日为股价下跌时净流入;近20日主力资金累计净流入6.1亿元,其中净流入天数为15日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729170356a6c7872f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729170356a6c7872f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2328871848.SGD","BK1583","BK1500","LU1969619763.USD","LU0307460666.USD","06160","BK1161","LU0588546209.SGD","BK1588"],"gpt_icon":0},{"id":"2555038763","title":"基金二季报陆续披露,中欧葛兰等基金经理加码创新药板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2555038763","media":"全景网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555038763?lang=zh_cn&edition=full","pubTime":"2025-07-29 15:19","pubTimestamp":1753773595,"startTime":"0","endTime":"0","summary":"随着基金二季报陆续披露, 创新药 板块成为众多基金经理关注的焦点,葛兰、谢治宇、傅鹏博、高楠等基金经理也纷纷加码创新药板块。展望三季度,在创新药领域,中欧基金葛兰在二季报中表示,看好全球合作深化与重要临床数据披露预期。睿远基金傅鹏博在二季度增加了医药板块配置,涉及创新药等子行业;永赢基金高楠管理的永赢睿信,在将 康方生物 、百济神州- U买进重仓股后,还在继续加码创新药。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729152818a4691f68&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729152818a4691f68&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09926","ONC","BK4526","06160","BK4139","01801"],"gpt_icon":0},{"id":"2555866160","title":"百济神州:百泽安获欧洲药品管理局人用药品委员会积极意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2555866160","media":"智通财经","labels":["productRelease"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555866160?lang=zh_cn&edition=full","pubTime":"2025-07-29 10:45","pubTimestamp":1753757135,"startTime":"0","endTime":"0","summary":"7月29日,据$百济神州$官微消息,7月28日,公司宣布欧洲药品管理局人用药品委员会发布积极意见,推荐批准百泽安联合含铂化疗用于存在高复发风险的可切除非小细胞肺癌成人患者的术前新辅助治疗,并在术后继续使用替雷利珠单抗单药进行辅助治疗。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322972.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百济神州:百泽安获欧洲药品管理局人用药品委员会积极意见","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","688235","BK4526","BK4087","06160","LU0588546209.SGD","BK0239","BK1500","LU2328871848.SGD","ONC","BK4139","BK1583","BK1588","LU1969619763.USD","LU0307460666.USD"],"gpt_icon":0},{"id":"2555702208","title":"智通港股早知道 | 育儿补贴制度实施方案发布 药明康德(02359)来自美国客户收入同比增长38.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555702208","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555702208?lang=zh_cn&edition=full","pubTime":"2025-07-29 07:28","pubTimestamp":1753745308,"startTime":"0","endTime":"0","summary":"育儿补贴制度实施方案发布,3岁以下婴幼儿每年补贴3600元中共中央办公厅、国务院办公厅发布《育儿补贴制度实施方案》,明确对3岁以下婴幼儿发放育儿补贴从2025年1月1日起,对符合法律法规规定生育的3周岁以下婴幼儿发放补贴。育儿补贴按年发放,现阶段国家基础标准为每孩每年3600元,发放补贴至婴幼儿年满3周岁。育儿补贴涉及港股婴幼儿食品板块。产品拟用于治疗成人轻度至中度阿尔茨海默型痴呆症状。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","06160","LU1997245094.SGD","LU2125910500.SGD","02552","BK1165","BK1588","BK1180","YANG","LU0456842615.SGD","LU1997245177.USD","LU1969619763.USD","06633","01328","BK1104","BK1510","LU0307460666.USD","IE0034224299.USD","BK1191","LU0588546209.SGD","LU1046422090.SGD","BK4614","BK1505","00236","BK1171","LU2328871848.SGD","LU2242644610.SGD","LU2488822045.USD","02359","HSTECH","BK0216","BK1156","BK1583","01157","BK1576","LU0052750758.USD","BK1161","LU1997244956.HKD","SG9999014674.SGD","BK1500","LU2495084118.USD","603259","LU2045819591.USD","LU0708995583.HKD","BK1548","BK1141","BK1578","LU0320764599.SGD","HSCEI"],"gpt_icon":1},{"id":"2555704118","title":"国内稀缺、研发实力强!7家创新药企手握重磅新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2555704118","media":"巨丰投顾","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555704118?lang=zh_cn&edition=full","pubTime":"2025-07-29 05:59","pubTimestamp":1753739961,"startTime":"0","endTime":"0","summary":"核心龙头业绩高速增长提及恒瑞医药上涨10%。创新药作为医药生物板块的核心投资主线,近期在政策、市场等多方面迎来积极变化。受益于海外订单的持续增长以及国内创新药研发的提速,这些企业整体盈利能力和成长性得到提升,2025年上半年业绩表现超出市场预期。2025年上半年创新药收入占比超45%,半年报业绩预增,其HER2 ADC药物临床数据优于同类产品,有望成为重磅炸弹级产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729060051a46849a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"3dc301cf42325347990d1936e0b8178f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729060051a46849a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","01276","06160","BK4139","BK4526","688235","600276","ONC","688180"],"gpt_icon":0},{"id":"2554783067","title":"百济神州百泽安®获欧洲药品管理局人用药品委员会积极意见,支持其用于非小细胞肺癌患者新辅助/辅助治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2554783067","media":"百济神州","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554783067?lang=zh_cn&edition=full","pubTime":"2025-07-28 18:04","pubTimestamp":1753697071,"startTime":"0","endTime":"0","summary":"此次CHMP的积极意见将有望惠及处在更早期治疗阶段的患者。百泽安是百济神州实体瘤产品组合的基石药物,已在多种肿瘤类型和疾病中展现出潜力。百泽安已在46个国家和地区获批,全球超过150万例患者接受了治疗。关于百济神州百济神州是一家注册地位于瑞士的全球肿瘤治疗创新公司,专注于为全世界的癌症患者研发创新抗肿瘤药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728180959a6c5c7be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728180959a6c5c7be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","06160","BK4526","ONC"],"gpt_icon":0},{"id":"2554476027","title":"港股异动 | 百奥赛图-B(02315)涨超3% 近日宣布与百济神州达成抗体分子全球许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2554476027","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554476027?lang=zh_cn&edition=full","pubTime":"2025-07-28 11:20","pubTimestamp":1753672815,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B涨超3%,截至发稿,涨2.64%,报21.35港元,成交额450.75万港元。消息面上,近日,据百奥赛图官微消息,公司宣布与全球肿瘤治疗创新公司百济神州达成抗体分子的全球许可协议。根据协议条款,百济神州将向百奥赛图支付首付款。据介绍,百济神州此前已获得百奥赛图RenMice全人抗体平台的授权使用许可,本次双方在已建立的良好合作基础上进一步将合作拓展至抗体分子授权许可领域,标志着双方合作的持续深化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322457.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","02315","LU2328871848.SGD","BK1583","BK4139","BK1500","BK4526","LU1969619763.USD","LU0307460666.USD","06160","BK1161","LU0588546209.SGD","688235","ONC","BK1588"],"gpt_icon":0},{"id":"2554877817","title":"百济神州-U股价微跌0.19% 二季度获201家基金重仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2554877817","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554877817?lang=zh_cn&edition=full","pubTime":"2025-07-25 02:33","pubTimestamp":1753382029,"startTime":"0","endTime":"0","summary":"截至2025年7月24日收盘,百济神州-U股价报237.68元,较前一交易日下跌0.45元,跌幅0.19%。当日成交量为21877手,成交金额达5.20亿元。百济神州-U属于医药生物行业,是一家专注于创新药物研发的生物科技企业。公司主要从事肿瘤、免疫肿瘤等领域的创新药物研发、生产和商业化。数据显示,2025年二季度末共有201家基金重仓持有百济神州-U,合计持股3850.52万股,占流通股比例达33.47%。在科创板公司中,百济神州-U的基金持股比例排名第二。7月24日,百济神州-U主力资金净流出453.23万元,占流通市值比例为0.02%。风险提示:投资有风险,入市需谨慎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725023955971c9964&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250725023955971c9964&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK0239","06160","ONC"],"gpt_icon":0},{"id":"2553078322","title":"新事丨罗氏终止TIGIT全部三期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2553078322","media":"健识局","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553078322?lang=zh_cn&edition=full","pubTime":"2025-07-24 20:30","pubTimestamp":1753360205,"startTime":"0","endTime":"0","summary":"在最新的管线中,PD-1联合TIGIT治疗非小细胞肺癌、肝癌的三期临床均已终止。这意味着罗氏针对TIGIT进行的三期临床全部终止。TIGIT靶点的价值是罗氏在2009年最先发现的。当时,罗氏的TIGIT+PD-L1联合疗法的效果曾一鸣惊人,一度被认为是PD-1之后的免疫新星。全球范围内,这几年TIGIT单抗预期快速变化:默沙东、罗氏等药企都已经历多次失败,留给TIGIT靶点成功的希望相当渺茫。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724203245a6bfb977&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724203245a6bfb977&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MRK","BK0060","LU1997244956.HKD","01276","688266","BK0183","LU1655091616.SGD","BK0239","LU0405327148.USD","LU1997245177.USD","LU1997245094.SGD","688235","LU1328615791.USD","600276","LU2495084118.USD","BK0028","01801","BK0012","LU2148510915.USD","LU1969619763.USD","BK0188","688177","BK0196","06160","LU1064131003.USD","LU2328871848.SGD","LU0405327494.USD","LU2488822045.USD","ONC","LU1064130708.USD"],"gpt_icon":1},{"id":"2553216134","title":"百济潜在 BIC 蛋白降解剂获批新临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2553216134","media":"Insight数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553216134?lang=zh_cn&edition=full","pubTime":"2025-07-23 16:28","pubTimestamp":1753259310,"startTime":"0","endTime":"0","summary":"7 月 23 日,CDE 官网显示,百济神州BGB-45035 片获批临床,用于治疗类风湿性关节炎。这是继特应性皮炎和结节性痒疹后,BGB-45035 获批的第三项临床。来源:CDE 官网BGB-45035 是一款靶向白细胞介素 1 受体相关激酶4的 蛋白降解剂。据百济介绍,BGB-45035 具有同类最佳潜力,在临床前模型中,相比 KT474,BGB-45035 可带来更快、更深度的 IRAK4 降解,且细胞因子抑制作用更强。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723173827a6bd0654&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723173827a6bd0654&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK0239","ONC","06160"],"gpt_icon":0},{"id":"2553575942","title":"券商资管系公募,排名来了!","url":"https://stock-news.laohu8.com/highlight/detail?id=2553575942","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553575942?lang=zh_cn&edition=full","pubTime":"2025-07-23 00:06","pubTimestamp":1753200372,"startTime":"0","endTime":"0","summary":"头部券商资管公募管理规模普遍增长Wind数据显示,截至二季度末,共有4家券商资管机构的公募基金资产管理总规模超千亿元。此外,相比于今年一季度末,头部券商资管的公募管理规模普遍增长,东方红资产管理、华泰证券资管规模增长均超200亿元,招商证券资管规模增长33亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723001401a45cdc20&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723001401a45cdc20&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","688443","ONC","01276","600276","688192","BK0239","688266","06160","09969","06990","688428"],"gpt_icon":0},{"id":"2553207288","title":"百济神州盘中异动 早盘快速上涨3.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553207288","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553207288?lang=zh_cn&edition=full","pubTime":"2025-07-22 09:44","pubTimestamp":1753148680,"startTime":"0","endTime":"0","summary":"2025年07月22日早盘09时44分,百济神州股票出现异动,股价急速拉升3.02%。截至发稿,该股报180.900港元/股,成交量74.7922万股,换手率0.05%,振幅3.25%。机构评级方面,在所有32家参与评级的机构中,97%的券商给予买入建议,3%的券商给予持有建议,无券商给予卖出建议。百济神州股票所在的生物技术行业中,整体涨幅为0.06%。百济神州公司简介:百济神州是一家全球性、商业阶段的生物科技公司,专注于研究、开发、生产以及商业化创新型药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722094440a6b96e65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722094440a6b96e65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","BK0239","06160"],"gpt_icon":0},{"id":"2553146441","title":"博时基金唐屹兵旗下博时上证科创板100ETF中报最新持仓,重仓百济神州","url":"https://stock-news.laohu8.com/highlight/detail?id=2553146441","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553146441?lang=zh_cn&edition=full","pubTime":"2025-07-21 07:10","pubTimestamp":1753053035,"startTime":"0","endTime":"0","summary":"证券之星消息,7月21日博时基金旗下唐屹兵管理的博时上证科创板100交易型开放式指数基金公布中报,近1年净值增长率45.36%。与上一季度相比,该基金前十大重仓股新增华虹公司,中科飞测,安集科技,纳芯微;其中百济神州持仓占比3.01%,为该基金第一大重仓股;恒玄科技,绿的谐波,乐鑫科技,铂力特等退出前十大重仓股;详细数据如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072100001574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","159982","06160","BK1161","BK0239","BK1588","000001.SH","688235","399300","588120","LU2328871848.SGD","LU1969619763.USD","LU0588546209.SGD","BK1500","LU0307460666.USD"],"gpt_icon":0},{"id":"2552626304","title":"百济神州(ONC)盘前涨近4% 机构料公司第二季收入按年升33%至12亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552626304","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552626304?lang=zh_cn&edition=full","pubTime":"2025-07-18 19:26","pubTimestamp":1752837999,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州(ONC)盘前涨近4%,截至发稿,报301.260美元 。 消息面上,野村发表报告,料百济神州第二季收入按年升33%至12亿美元,与市场预期一致。该行预测百悦泽维持市场领导地位,次季销售按年升39%至8.84亿美元,其中美欧销售分别按年升35%及80%,至6.47亿及1.4亿美元。百泽安内地市场销售料按年升15%至1.82亿美元。此外,摩根大通分析师Jessica Fye维持百济神州买入评级,并将目标价从321美元上调至345美元。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"290592","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","LU0307460666.USD","BK1583","BK4526","LU0588546209.SGD","LU1969619763.USD","LU2328871848.SGD","688235","06160","BK4139","BK1500","BK1161","ONC","BK1588"],"gpt_icon":0},{"id":"2552432784","title":"鹏华基金苏俊杰旗下鹏华上证科创板100ETF中报最新持仓,重仓百济神州","url":"https://stock-news.laohu8.com/highlight/detail?id=2552432784","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552432784?lang=zh_cn&edition=full","pubTime":"2025-07-18 07:10","pubTimestamp":1752793826,"startTime":"0","endTime":"0","summary":"证券之星消息,7月18日鹏华基金旗下苏俊杰管理的鹏华上证科创板100交易型开放式指数基金公布中报,近1年净值增长率46.46%。与上一季度相比,该基金前十大重仓股新增华虹公司,中科飞测,安集科技,纳芯微;并对百济神州增仓3.02万股,为该基金第一大重仓股;恒玄科技,绿的谐波,铂力特,乐鑫科技等退出前十大重仓股;详细数据如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071800004958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1500","LU2328871848.SGD","BK0239","159982","000001.SH","588120","BK1588","06160","LU0588546209.SGD","LU1969619763.USD","399300","BK1161","688235","BK1583","LU0307460666.USD"],"gpt_icon":0},{"id":"2552871484","title":"全网打捞:下一个大BD","url":"https://stock-news.laohu8.com/highlight/detail?id=2552871484","media":"阿基米德Biotech","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552871484?lang=zh_cn&edition=full","pubTime":"2025-07-17 21:06","pubTimestamp":1752757573,"startTime":"0","endTime":"0","summary":"今天,你不能轻视任何一家Biotech,因为一旦达成BD就翻身。据医药魔方,2025H1,中国创新药License out总金额接近660亿美元,赶超2024全年BD交易总额。今天我们越过旧山丘,与新世界撞个满怀,在可见范围内尽力打捞下一个潜在的重磅BD。HLX43进展神速,获多国批准开展NSCLC国际多中心II期临床,是全球首个进入临床II期的PD-L1 ADC,引领强效低毒ADC全球开发进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717211513a4513799&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717211513a4513799&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02696","BK0060","LU2328871848.SGD","LU1655091616.SGD","01801","LU1969619763.USD","BK0239","BK0188","LU0405327148.USD","LU0405327494.USD","600276","LU1064131003.USD","01093","LU2148510915.USD","LU2495084118.USD","LU1997244956.HKD","BK0012","LU1997245094.SGD","LU2488822045.USD","BK0196","BK0183","LU1997245177.USD","BK0028","LU1328615791.USD","LU1064130708.USD","01877","06160"],"gpt_icon":0},{"id":"2552438772","title":"百济神州07月17日获主力大幅加仓2.2亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552438772","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552438772?lang=zh_cn&edition=full","pubTime":"2025-07-17 16:15","pubTimestamp":1752740140,"startTime":"0","endTime":"0","summary":"07月17日, 百济神州股价涨10.62%,报收183.30元,成交金额20.6亿元,换手率0.81%,振幅10.80%,量比2.09。百济神州今日主力资金净流入2.2亿元,连续5日净流入,上一交易日主力净流入2270.2万元。近一年数据显示,该股主力连续5日净流入后,次日上涨概率为60.00%,平均涨幅为2.51%。该股近5个交易日上涨19.44%,主力资金累计净流入3.4亿元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流入3.7亿元,其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717171409a6af6b5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717171409a6af6b5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1500","LU1969619763.USD","BK1583","LU2328871848.SGD","06160","BK1588","BK1161","LU0588546209.SGD","LU0307460666.USD"],"gpt_icon":0},{"id":"2552058901","title":"创新药再获热炒 恒生医疗ETF涨4.37% 乐普生物(02157)涨两成 机构称价值重估驱动行情","url":"https://stock-news.laohu8.com/highlight/detail?id=2552058901","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552058901?lang=zh_cn&edition=full","pubTime":"2025-07-17 14:08","pubTimestamp":1752732500,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药再获热炒,恒生医疗ETF暂涨4.37%,乐普生物-B 涨20.55%,康诺亚-B涨14.7%,康方生物涨11.75%,三生制药涨11.09%,百济神州涨10.02%,科伦博泰生物-B涨9.29%,金斯瑞生物科技涨8.45%,先声药业涨8.44%。国家医保局于本周二宣布启动第11轮国家药品集采,涉及55种药品。医院需在7月16日至7月31日期间报告采购量。值得注意的是,《通知》首次附上了68种符合评价标准但未纳入第11批VBP的产品名单,并具体说明了排除原因。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1962441","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","01530","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU0196878994.USD","06990","HK0000320264.USD","513060","LU1720050803.USD","BK1500","LU2488822045.USD","BK1588","BK1583","LU2328871848.SGD","BK1191","BK1593","BK1587","LU0417516571.SGD","HK0000320223.HKD","LU1794554557.SGD","HK0000306685.HKD","01548","BK1576","IE00BPRC5H50.USD","LU0588546209.SGD","LU1969619763.USD","02096","LU0348783233.USD","BK1574","06160","02157","159992","BK1141","02162","06978","HK0000306701.USD","LU0348784397.USD","LU0307460666.USD","BK1161"],"gpt_icon":0},{"id":"2552412721","title":"百济神州-U股价微跌0.56% 生物制药板块活跃度受关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2552412721","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552412721?lang=zh_cn&edition=full","pubTime":"2025-07-17 01:56","pubTimestamp":1752688566,"startTime":"0","endTime":"0","summary":"百济神州-U7月16日收盘报239.94元,较前一交易日下跌0.56%。当日股价波动区间为237.79元至246.28元,成交金额达5.01亿元。该公司属于生物制品行业,专注于创新型分子靶向药物和肿瘤免疫药物的研发。作为一家全球性生物科技公司,百济神州在肿瘤治疗领域拥有多个在研产品管线。7月16日数据显示,百济神州-U主力资金净流出2927.45万元。该股当前总市值为3694.74亿元,流通市值276.06亿元。风险提示:股市有风险,投资需谨慎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071702031197a8b94d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071702031197a8b94d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","ONC","BK0239","688235"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":0.033},{"period":"1month","weight":0.2307},{"period":"3month","weight":0.2174},{"period":"6month","weight":0.3126},{"period":"1year","weight":0.8643},{"period":"ytd","weight":0.6612}],"compareEarnings":[{"period":"1week","weight":0.0227},{"period":"1month","weight":0.0526},{"period":"3month","weight":0.1615},{"period":"6month","weight":0.2639},{"period":"1year","weight":0.5018},{"period":"ytd","weight":0.2743}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"BeiGene Ltd是一家全球生物技术公司,致力于为全球癌症患者发现和开发肿瘤治疗方法。该公司已发现并开发三种批准药物,包括BRUKINSA,一种布鲁顿酪氨酸激酶的小分子抑制剂,用于治疗各种血癌;TEVIMBRA(tislelizumab),一种抗PD-1抗体免疫疗法,用于治疗各种实体瘤和血癌;以及是聚ADP核糖聚合酶1(PARP1)和PARP2的选择性小分子抑制剂pamiparib。该公司已获得在美国、中华人民共和国(中国)、欧盟、英国、加拿大、澳大利亚和其他国际市场销售BRUKINSA,在欧盟和中国销售替雷利珠单抗,以及在中国销售帕米帕尼的批准。它还专注于在Amgen Inc独家授权下在中国商业化癌症药物,如XGEVA、BLINCYTO、KYPROLIS等。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.009815},{"month":2,"riseRate":0.571429,"avgChangeRate":0.046604},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.052519},{"month":4,"riseRate":0.428571,"avgChangeRate":0.037509},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.052709},{"month":6,"riseRate":0.428571,"avgChangeRate":0.007027},{"month":7,"riseRate":0.857143,"avgChangeRate":0.097108},{"month":8,"riseRate":0.833333,"avgChangeRate":0.065797},{"month":9,"riseRate":0.428571,"avgChangeRate":0.01247},{"month":10,"riseRate":0.571429,"avgChangeRate":-0.017395},{"month":11,"riseRate":0.571429,"avgChangeRate":0.120457},{"month":12,"riseRate":0.142857,"avgChangeRate":-0.068807}],"exchange":"SEHK","name":"百济神州","nameEN":"BEIGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,06160,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}